Related Experiment Video
Updated: Feb 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
An Update on Anticoagulation in Atrial Fibrillation
1Deakin University, Geelong, Vic, Australia.
Insights
Direct-acting oral anticoagulants (DOACs) offer a new approach to preventing strokes in atrial fibrillation (AF) patients. DOACs are expected to become the primary stroke prevention therapy for non-valvular AF.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) increases stroke risk, necessitating anticoagulation.
- Warfarin was the standard anticoagulant for stroke prevention in AF.
- Novel direct-acting oral anticoagulants (DOACs) have emerged as alternatives.
Purpose of the Study:
- To discuss the paradigm shift in anticoagulation therapy for AF.
- To highlight the role of DOACs in stroke prevention.
- To guide physicians on current anticoagulation strategies for AF.
Main Methods:
- Review of current anticoagulation guidelines and clinical evidence.
- Comparison of warfarin with DOACs for stroke prevention in AF.
- Analysis of treatment philosophy changes in AF management.
Main Results:
- DOACs represent a significant advancement in stroke prevention for AF.
- The focus of treatment decisions is shifting from 'when to use' to 'when not to use' anticoagulation.
- Warfarin remains relevant for specific patient subgroups.
Conclusions:
- DOACs are poised to become the predominant therapy for stroke prevention in non-valvular AF.
- Physicians must adapt to new treatment algorithms considering DOACs.
- Anticoagulation management in AF has entered a new era with DOAC availability.
Abstract:
Cerebrovascular accidents related to atrial fibrillation (AF) are potentially preventable with anticoagulation. Until recently, warfarin was the only proven anticoagulant to be effective in stroke prevention, however the novel, direct acting oral anticoagulants (DOACs) are now available, triggering a paradigm shift in treatment philosophy. Today, physicians need to consider in which patients anticoagulation should not be used rather than, as in the past, deciding in which patients it should be used. Although warfarin will continue to have a place in managing some patients with AF, in the future, the DOACs should be the predominant therapy for stroke prevention in patients with non-valvular AF.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

